Company Filing History:
Years Active: 2006-2008
Title: Innovations of Rui Li in Integrin Polypeptides
Introduction
Rui Li is an accomplished inventor based in Medford, MA (US). He has made significant contributions to the field of biochemistry, particularly in the development of variant integrin polypeptides. With a total of 3 patents, his work has implications for therapeutic applications and antibody generation.
Latest Patents
Rui Li's latest patents include innovative polypeptides that comprise all or part of a variant integrin α subunit A domain. These polypeptides exist predominantly in a high affinity conformation, which is crucial for their functionality. One of his notable inventions involves altering a crucial isoleucine or glutamic acid residue, allowing for selective impairment of binding to activation-dependent ligands. This innovation is particularly useful in screening assays aimed at identifying molecules that enhance binding capabilities. Another patent focuses on high affinity integrin polypeptides, which can be derived from any integrin α or β subunit and are also beneficial for therapeutic uses.
Career Highlights
Rui Li is associated with The General Hospital Corporation, where he continues to advance research in integrin polypeptides. His work has garnered attention for its potential applications in medical therapies and diagnostics.
Collaborations
Rui Li has collaborated with notable colleagues, including M Amin Arnaout and Jian-Ping Xiong. Their combined expertise contributes to the innovative research being conducted in the field of integrin biology.
Conclusion
Rui Li's contributions to the development of variant integrin polypeptides highlight his role as a significant inventor in the field of biochemistry. His patents pave the way for advancements in therapeutic applications and antibody generation.